as on September 18, 2025 at 1:29 am IST
Day's Low
Day's High
1.93%
Downside
2.37%
Upside
52 Week's Low
52 Week's High
14.14%
Downside
103.81%
Upside
Check Summit Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$13.5B
EPS (TTM)
-0.7135
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-15.59
Industry PE ratio
10.127857142857144
P/B Ratio
0PEG Ratio
0EBITDA
-759.2M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
579922300.00%
Track how Summit Therapeutics Inc P/E has moved over time to understand its valuation trends.
Summit Therapeutics Inc in the last 5 years
Lowest (0.00x)
September 18, 2025
Today (-15.59x)
September 18, 2025
Industry (10.13x)
September 18, 2025
Highest (-0.61x)
April 30, 2023
Today’s Price to Earnings Ratio: -15.59x
Compare market cap, revenue, PE, and other key metrics of Summit Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $13.5B | NA | -15.59 | 0.00% | |
BUY | $60.5B | 248.74% | -505.15 | -12.96% | |
NA | $38.7B | NA | NA | -3.89% | |
BUY | $99.3B | 45.88% | 27.56 | 31.86% | |
BUY | $60.9B | 5.45% | 14.49 | 31.37% |
The Summit Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Summit Therapeutics Inc investment value today
Current value as on today
₹78,336
Returns
Returns from Summit Therapeutics Inc Stock
Dollar Returns*
₹4,598 (+4.6%)
Based on 7 analysts
85.71%
Buy
14.29%
Hold
0.00%
Sell
Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Summit Therapeutics Inc. Average target price of $33.01
Get share price movements and forecasts by analysts on Summit Therapeutics Inc.
What analysts predicted
45.14%UPSIDE
Target Price
$33.01
Current Price
$18.11
Analyzed by
7 Analysts
Target
$33.01
Summit Therapeutics Inc target price $33.01, a slight upside of 45.14% compared to current price of $18.11. According to 7 analysts rating.
Investment in Summit Therapeutics Inc Shares on INDmoney has grown by 252.63% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:252.63% versus previous 30 day period
Search interest for Summit Therapeutics Inc Stock has increased by 31% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:31% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Best in 3 Years
In the last 3 years, SMMT has outperformed top 5 stocks with highest market-cap in its industry
Price Rise
In the last 3 years, SMMT stock has moved up by 1302.3%
Against Peers
In the last 1 year, Beone Medicines Ltd has given 68.4% return, outperforming this stock by 94.7%
Profit Down
Netprofit is down for the last 4 quarters, -56.25M → -565.70M (in $), with an average decrease of 270.3% per quarter
Revenue Fall
Revenue is down for the last 3 quarters, 235.0K → -235.0K (in $), with an average decrease of 100.0% per quarter
Organisation | Summit Therapeutics Inc |
Headquarters | 601 Brickell Key Drive, Miami, FL, United States, 33131 |
Industry | Health Technology |
CEO | Mr. Robert W. Duggan |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director |
Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
Mr. Dave Gancarz | Chief Business & Strategy Officer |
Ms. Shelley D. Spray | Chief Education & Brand Officer |
Dr. Allen S. Yang M.D., Ph.D. | Chief Medical Officer |
Dr. Laura Q. M. Chow M.D. | Senior Vice President of Clinical Development |
Mr. Robert W. Duggan | Co-CEO & Executive Chairman |
Mr. Manmeet Singh Soni CPA | COO, CFO & Director |
Dr. Fong Clow | Chief Biometrics Officer |
Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer |
Summit Therapeutics Inc share price today is $18.11 as on at the close of the market. Summit Therapeutics Inc share today touched a day high of $18.54 and a low of $17.76.
Summit Therapeutics Inc share touched a 52 week high of $36.91 on and a 52 week low of $15.55 on . Summit Therapeutics Inc stock price today i.e. is closed at $18.11,which is 50.93% down from its 52 week high and 16.46% up from its 52 week low.
Summit Therapeutics Inc market capitalisation is $0.01T as on .
Indian investors can start investing in Summit Therapeutics Inc (SMMT) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Summit Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Summit Therapeutics Inc share’s latest price of $18.11 as on September 18, 2025 at 1:29 am IST, you will get 0.5522 shares of Summit Therapeutics Inc. Learn more about
fractional shares .